[Federal Register: April 9, 2003 (Volume 68, Number 68)]
[Notices]
[Page 17403]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr09ap03-81]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importation of Controlled Substances; Notice of Application
Pursuant to section 1008 of the Controlled Substances Import and
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substances in Schedule I or II and prior to issuing a
registration under section 1002(a) authorizing the importation of such
a substance, provide manufacturers holding registrations for the bulk
manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Sec. 1301.34 of Title 21, Code of
Federal Regulations (CFR), notice is hereby given that on February 14,
2003, Boehringer Ingelheim Chemicals, Inc. 2820 N. Normandy Drive,
Petersburg, Virginia 23805, made application by renewal to the Drug
Enforcement Administration to be registered as an importer of
Phenylacetone (8501), a basic class of controlled substance listed in
Schedule II.
The firm plans to import Phenylacetone for the bulk manufacture of
amphetamine.
Any manufacturer holding, or apply for, registration as a bulk
manufacturer of this basic class of controlled substance may file
written comments on or objections to the application described above
and may, at the same time, file a written request for a hearing on such
application in accordance with 21 CFR 1301.43 in such form as
prescribed by 21 CFR 1316.47.
Any such comments, objections, or requests for a hearing may be
addressed, in quintuplicate, to the Deputy Assistant Administrator,
Office of Diversion Control, Drug Enforcement Administration, United
States Department of Justice, Washington, DC 20537, Attention: Drug
Operations Section, Domestic Drug Unit (ODOD), and must be filed no
later than May 9, 2003.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e), (f). As noted as a previous notice at 40 FR 43745-46 (Sepember 23,
1975), all applicants for registration to import basic class of any
controlled substance in Schedule I or II are and will continue to be
required to demonstrate to the Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement Administration that the
requirements for such registration pursuant to 21 U.S.C. 958(a), 21
U.S.C. 823(a), and 21 CFR 1311.452(a), (b), (c), (d), (e), and (f) are
satisfied.
Dated: March 21, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 03-8585 Filed 4-8-03; 8:45 am]
BILLING CODE 4410-09-M